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摘要
目的:评估糖尿病视网膜病变(DR)严重程度与血清胱抑
素 C和急性时相反应指标的相关性,包括红细胞沉降率
(ESR)和超敏 C反应蛋白(hs-CRP)。
方法:研究纳入了 1mo 内就诊的所有糖尿病视网膜病患
者。 患者均记录人口统计学数据。 行眼科检查,同时检测
糖化血红蛋白(HbA1c)、ESR、hs -CRP 和血清胱抑素 C
水平。
结果:研究包括 67 例糖尿病患者,其中 19 例(28. 3% )无
视网膜病变患者,22 例(32. 8% )非增殖型视网膜病变患
者和 26 例(38. 8% )增殖型视网膜病变患者。 三组间平均
年龄、性别分布、平均糖尿病病程、高血压和血脂异常患病
率、吸烟状况以及 HbA1c 水平无明显差异。 随着视网膜
病变发展,平均血清胱抑素 C 水平显著提高,三组分别为
1. 1依0. 48,1. 22依0. 38,1. 71依0. 92 (P=0. 007)。 在多元回
归分析中,仅血清胱抑素 C 与糖尿病视网膜病变严重程
度有关(P=0. 025)。
结论:研究表明,在独立于急性时相反应指标,血清胱抑素
C水平随 DR加重升高。 因此,该结论可作为初级医护人
员区分高危患者的标志。
关键词:血清胱抑素 C;红细胞沉降率;超敏 C 反应蛋白;
糖尿病视网膜病变;炎症反应标志物;急性时相反应物
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Abstract
誗AIM: To evaluate correlation of cystatin - C (Cys - C)
with severity of diabetic retinopathy ( DR ) and acute
phase reactants, including erythrocyte sedimentation rate
(ESR) and high-sensitivity C-reactive protein (hs-CRP) .
誗METHODS: All diabetic patients who were referred for
diabetic retinopathy ( DR ) screening during 1mo were
enrolled. Demographic data were recorded. All patients
have undergone full ophthalmic exam. At the same day,
all patients were tested for hemoglobin A1c ( HbA1c),
ESR, hs-CRP, and Cys-C serum levels.
誗 RESULTS: Sixty seven diabetics were enrolled,
including 19 (28. 3%) without retinopathy, 22 (32. 8%)
non - proliferative retinopathy, and 26 ( 38. 8%)
proliferative retinopathy patients. The mean age, sex
distribution, mean duration of diabetes, prevalence of
hypertension and dyslipidemia, smoking status and
HbA1c levels were not significantly different among the
three groups. The mean levels of Cys - C increase
significantly as retinopathy progress [1. 1 依 0. 48; 1. 22 依
0郾 38; 1. 71 依 0. 92 (P = 0. 007), respectively] . In multiple
regression analysis, just Cys - C was significantly
associated with severity of DR (P= 0. 025) .
誗CONCLUSIONS: This study revealed that serum levels
of Cys - C increase while DR progress independently of
acute phase reactants. Therefore, it could be used as an
associated marker by primary care physicians to
distinguish patients at higher risk of severe DR. Larger
randomized studies are warranted to confirm findings.
Reviewing physiological role of the Cys-C, we proposed
that the Cys-C may be a protective response to catalytic
stress rather than being a pathogenic factor in
microangiopathies.
誗 KEYWORDS: cystatin - C; erythrocyte sedimentation
rate; high - sensitivity C - reactive protein; diabetic
retinopathy; inflammatory markers; acute phase reactants
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INTRODUCTION
D iabetic retinopathy (DR) is a microvascular comorbidityof diabetes mellitus ( DM ). Current guideline for
diabetic retinopathy screening in DM type 1 is mainly based
on duration of disease but it has been reported that hemoglobin
A1c (HbA1c) and duration of disease can only predict 11 %
of patients with DR[1] . To adjust screening schedules,
investigation of further associated risk factors are necessitated.
It is not possible to fully predict, prevent, and treat DR until
we know the role of all factors in pathophysiology of the
disease. The pathogenesis of DR is not fully understood but it
is believed that complex metabolic dysfunction, oxidative
damages, and inflammatory mechanisms may contribute to
it[2-6] . To find new associated factors of DR, one may explore
suggested risk factors of other microvasculopathies in DM.
Diabetic retinopathy and nephropathy are co-findings in many
diabetics, common contributing factors may explain this
concordance[7] .
In recent years, several clinical studies have investigated
serum levels of cystatin-C (Cys-C) in various diseases[8-16] .
Cys-C is an endogenous cysteine proteinase inhibitor which is
produced by all nucleated cells. Its serum concentration is
minimally dependent on protein intake and body mass. It is
mainly catabolized by the kidneys[17] . It found to be superior
to serum creatinine in distinguishing impaired kidney function
and a strong predictor of diabetic nephropathy ( DN ).
Moreover, it could predict DN earlier even in pre -diabetic
state[8] . In addition, it is associated with other vasculopathies
such as diabetic foot[9] and cardiovascular disease[10] . Few
studies have assessed correlation of the Cys - C levels with
severity grading of DR which revealed that its serum level is
related to severity of DR[12-16] . Not only Cys-C is elevated in
those with DR[14] but also normal populations with elevated
Cys-C levels found to be at greater risk of DR[12] . Those with
higher Cys - C levels reported to progress to more severe
DR[14] . Altuno姚glu et al[11] found a correlation between Cys-C
levels and acute - phase reactants, including erythrocyte
sedimentation rate ( ESR ) and CRP in non - diabetic
nephropathy. Sun et al[16] speculated that higher serum Cys-
C may lead to inflammation thus may increase CRP.
Correlations of Cys -C levels with ESR and high - sensitivity
C-reactive protein (hs-CRP) have not been reported yet in
patients with DR.
In this study, the association of Cys-C levels to acute phase
reactants ( ESR and hs - CRP, as general inflammatory
markers) and severity of DR in diabetics without DN have
been investigated. Furthermore, physiological roles of Cys-C
were reviewed.
SUBJECTS AND METHODS
Study Subjects, Area, and Design摇 All patients with type
2 DM who were referred for DR screening to the eye clinic of
Vali-e-Asr Hospital (Birjand City, South Khorasan, Iran)
during 1mo ( September 2015 ) were recruited. Exclusion
criteria included failure to obtain consent, presence of any
systemic disease other than DM including chronic kidney
disease (CKD), inflammatory and collagen vascular diseases,
and any history of surgery including eye surgery. Patients with
DN also have been excluded. These were assessed by history
taking and reviewing their past laboratory information.
Past medical history of patients was recorded, including age,
sex, duration of diabetes, history of hypertension ( HTN),
history of smoking, and lipid profile. The study was adherent
to the principles of the Declaration of Helsinki and approved
by ethical committee of ophthalmology department.
Ophthalmic Exam摇 All patients have undergone full dilated
ophthalmoscopy by two examiners to grade DR based on
International Clinical Disease Severity Scale[18] . In case of
any discrepancy, patients were re - examined by either of
ophthalmologists to resolve it.
Collection and Processing of Blood Samples摇 At the same
day of exam, venous blood samples of all patients were
collected from antecubital fossa and tested for ESR ( by
Westergren method ), hs - CRP ( by Hitachi 7080; TIA
method), Cys - C ( by immunoturbidometry method), and
HbA1c levels.
Statistical Analysis摇 The SPSS software (version 16, SPSS,
Inc. , Chicago, IL, USA) was utilized in data analysis. One-
way ANOVA and Kruskal - Wallis h - tests were used to
examine parametric and nonparametric variables,
respectively. Bivariate correlation analysis of Spearman was
performed to find any correlation between Cys-C, ESR, hs-
CRP, HbA1c, and duration of disease. Multiple regression
analysis was performed to find if any of factors including
gender, age, duration of disease, HbA1c, Cys-C, ESR, hs-
CRP, smoking state, dyslipidemia, and HTN history are
independently associated to severity of DR(P<0. 05).
RESULTS
In this prospective study, a total of 67 diabetic patients were
enrolled. The study groups included 19 (28. 3% ) patients
with no apparent DR (NDR), 22 (32. 8% ) patients with
non-proliferative DR (NPDR), and 26 (38. 8% ) patients
with proliferative DR ( PDR). The sex distribution ( P =
0郾 18), mean age (P=0. 13), duration of DM after diagnosis
(P=0. 17), HbA1c levels (P=0. 44), prevalence of history
of HTN (P= 0. 96), prevalence of dyslipidemia (P = 0. 36)
and prevalence of positive smoking history (P = 0. 22) were
not significantly different among the three groups. Table 1
summarizes demographic information of the three study
groups.
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Table 1摇 Demographic information of study groups
Variable NDR NPDR PDR P
Patients 19 22 26
Age (y) 54. 47依9. 5 59. 18依10. 09 59. 54依7. 38 0. 13
Sex (F / M) 10 / 9 6 / 16 13 / 13 0. 18
Duration (y) 8. 45依4. 47 11. 65依5. 96 11. 60依5. 05 0. 17
Hypertension (% ) 57. 89 59. 09 61. 53 0. 96
Dyslipidemia (% ) 63. 15 40. 9 53. 84 0. 36
Smoking (% ) 26. 31 31. 81 11. 53 0. 22
HbA1c (% ) 7. 33依0. 44 7. 25依0. 8 7. 08依0. 7 0. 44
NDR: No apparent diabetic retinopathy; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic retinopathy; HbA1c:
Hemoglobin A1c; Categorical data are presented as n (% ); Continuous data are presented as mean依SD deviation.
Table 2摇 Cys-C, ESR, and hs-CRP serum levels in the study groups
Variables NDR NPDR PDR P
Cys-C (mg / L) 1. 1依0. 48 1. 22依0. 38 1. 71依0. 92 0. 007
ESR (mm / h) 13. 37依7. 04 13. 09依9. 25 20. 08依18. 68 0. 13
hs-CRP (mg / mL) 9. 05依9. 7 7. 73依9. 28 7. 58依4. 86 0. 81
Cys-C: Cystatin - C; ESR: Erythrocyte sedimentation rate; hs - CRP: High - sensitivity C - reactive protein; NDR: No apparent diabetic
retinopathy; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic retinopathy; P<0. 05 (significant differences between
the three groups).
Table 3摇 The bivariate correlation of Cys-C, ESR, hs-CRP, HbA1c, and duration of diabetes mellitus
Variables Cys-C (mg / L) ESR (mm / h) hs-CRP (mg / mL) HbA1c (% ) Duration (y)
Cys-C (mg / L) - <0. 001 0. 13 0. 72 0. 84
ESR (mm / h) <0. 001 - 0. 004 0. 41 0. 85
hs- CRP (mg / mL) 0. 13 0. 004 - 0. 9 0. 86
CYS-C: Cystatin-C; ESR: Erythrocyte sedimentation rate; hs-CRP: High-sensitivity C-reactive protein; HbA1c: Hemoglobin A1c; All
values are P of two-tailed significance; Analyzed by Pearson蒺s bivariate correlation test; P<0. 05 considered significant.
Although the study demonstrated no significant difference in
terms of mean acute phase reactants levels (ESR, P = 0. 13;
hs-CRP, P=0. 81) levels, there were significant differences
in mean levels of Cys -C (P = 0. 007) among the groups.
Table 2 compares study groups in terms of mean ESR, hs -
CRP, and Cys-C levels.
In Bivariate(Spearman) correlation analysis (Table 3), there
was a correlation between Cys-C and ESR (P<0. 001) but
neither hs -CRP (P = 0. 13) nor HbA1c (P = 0. 72) and
duration of disease (P=0. 84).
A multiple regression analysis was run to find factors
associated to severity of DR from gender, age, duration of
disease, HbA1c, Cys - C, ESR, hs - CRP, smoking state,
dyslipidemia, and HTN history. Although these variables are
marginally statistically significantly associated to severity of
DR [F (10, 57 ) = 1. 942, P = 0. 058 ] with an R2 of
0郾 255, but only Cys-C found to be an independent associated
factor (P=0. 025).
DISCUSSION
Results of current study are in line with previous reports
concerning that Cys - C levels are correlated to severity of
DR[12-16] . Cys-C levels in normal population under and over
50y of age are in range of 0. 53-0. 92 and 0. 58-1. 02 mg / L,
respectively[19] . The mean Cys-C levels in all three groups of
this study were above the normal levels ( >0. 48依1. 1 mg / L;
range: 0. 4 -3. 91 mg / L) . The mean Cys-C levels in PDR
group was 0. 92依1. 71 mg / L. He et al[14] also reported levels
greater than 1. 25 mg / L in severe NPDR and PDR. They
found that Cys-C levels greater than 1. 25 mg / L increase the
risk of severe DR by 11 - fold. They suggested that Cys -C
levels could be utilized as an efficient and inexpensive
screening index to predict the sight - threatening diabetic
retinopathy (STDR). They recommended that it may decrease
rising financial burden of DR screening.
There is no earlier report demonstrating that Cys-C in DR is
correlated to ESR, hs-CRP, or inflammatory markers. In this
study, Cys-C levels found to be correlated to ESR but not
hs-CRP or HbA1c levels. In multiple regression analysis,
Cys-C was the sole independent risk factor of DR. Font et
al[20] also reported that Cys-C levels are not associated with
inflammatory markers (CRP, interleukin-6, and fibrinogen)
in non-diabetic patients with CKD. It should be emphasized
that many factors may influence Cys-C levels, including age,
sex, height, weight, smoking status, HTN, cardiovascular
diseases, and inflammatory conditions beyond the kidney
function[21-22] . For an instance, ectatic vascular diseases are
correlated with lower Cys-C levels but coronary artery disease
is correlated with higher levels of Cys - C[21-22] . While
interpreting the results, one should consider these
confounding factors which may influence the significance of
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findings.
In our series, there was no association betweenthe ESR levels
and DR severity. In bivariate analysis, the ESR levels were
correlated to Cys-C and hs-CRP, but not HbA1c levels. The
ESR levels were not found as independent risk factor of DR
severity in multivariate regression analysis. The correlation of
the ESR and DR has yet to be fully published. Although
serum concentrations of Interleukin ( IL ) - 1beta, tumor
necrosis factor (TNF)-alpha, and vascular endothelial growth
factor ( VEGF) as contributing factors of DR development
found to be correlated to ESR[23], But it has been reported
that there is no difference between diabetics with and without
DR and normal population in case of ESR levels[24] . The ESR
is non-specific inflammatory marker which is affected by any
factors that alters adhesiveness and aggregation of red blood
cells (RBC). These are affected by many other factors such
as immunoglobulin, CRP, cholesterol, triglycerides,
albumin, high fibrinogen levels, and also anemia[25] . To fully
investigate the correlation of ESR and DR, larger studies are
warranted.
Although some studies found that higher CRP levels may be
negatively correlated to DR[26], but in some other studies hs-
CRP levels was positively related to DR and it was suggested
to be correlated to vascular complications[27] . In a recent
meta-analysis, it was found that the CRP levels might be
used as a biomarker to determine the severity of DR[28] .
Remarkably, metabolic control ( reduced HbA1c, fasting
blood glucose, and triglyceride) can decrease the hs - CRP
levels. Interestingly, PDR group in this study had a better
metabolic control which was reflected by having lower HbA1c
than the other two groups. This could be justified by better
control among patients when severe complications of DM
initiate to show off and put patients on alarm. In current
series, there was no association between hs-CRP and Cys-C
levels nor severity of DR. Better control among patients with
more severe disease, may explain why no correlation between
grade of hs-CRP and neither DR nor Cys-C was found. The
hs-CRP levels were affected by sex, age, ethnicity, weight,
DM type, hyperglycemic control drugs type, glycemic control,
lipid profile, smoking history, hormone replacement therapy,
and various medications[28-30] . Any discrepancy between the
three groups in matter of these confounding factors may
influence the repeatability of results of the study.
There were evidences that retinal pigment epithelium (RPE)
secrets Cys-C which previously thought to play a role in blood
vessel wall disintegrity, inflammation, neurodegeneration,
neovascularization process[8], and macular degenration[31] .
Domingueti et al[15] found that endothelial dysfunction and
hypercoagulability biomarkers are in association with Cys -C
levels in DM type 1 patients with DR. Therefore, it was
speculated that accumulation of Cys - C in endothelial cells
may play a role in DR pathogenesis. Sun et al[16] proposed
that higher Cys-C levels in serum could be taken up into the
retinal pigment layer and interfere with endothelial pump
activity which may lead to inflammation and CRP rise. These
were contrary to findings of current study that there was no
association between Cys - C and CRP. Although there were
large cohorts that reported a correlation between inflammation
status and Cys - C[22-33], but there were recent reports that
CRP levels were not correlated to Cys-C levels in important
diseases[34-35] . Interestingly, recent studies also challenged
this correlation and supports finding of current study, they
demonstrated that not only Cys - C is not correlated to
inflammatory status of patients but also it is a marker of
successful aging[34,36] .
It has been found that lower levels of Cys - C or defective
mutant Cys-C is correlated with hereditary cystatin-C amyloid
angiopathy, age related macular degeneration,
atherosclerosis, abdominal aortic aneurysm, Alzheimer蒺s
disease and poorer prognosis in breast cancer. These were
justified by either amyloid formation or increased proteinase
activity. Moreover, Cys - C has demonstrated to have
protective effects against various oxidative stresses that induce
cell death[37] . Cysteine protease inhibitors also suggested to
be used for treatment of neurodegenerative diseases[38] .
Hence, Cys - C may have a protective rather than harmful
role. Therefore, we reviewed the physiological tasks of Cys-C
to propose a new role for it in pathogenesis of DR.
There is an association between insulin resistance and protein
oxidative stress which leads to formation of protein oxidation
products then inflammation and overproduction of resistin,
TNF-琢, and IL -6[39] . In diabetics, carbonylated proteins
levels were elevated which were vulnerable to proteolysis and
the markers of oxidative stress. Cys - C inhibits cysteine
protease which is remarkable enzymes in proteolysis and
apoptosis[40] . Cys -C expression is stimulated by stress may
play a role in inhibitory regulation of apoptosis in oxidative
stress[41] . Furthermore, Cys - C reduces the expression and
release of IL-1茁 and TNF -琢[42] . These findings could be
translated to this: Cys-C inhibits proteolysis and apoptosis,
so decrease the possible inflammatory response. Elevated Cys
-C in diabetics could be a protective response of stressed cells
rather than being interpreted as harmful accumulates which
were absorbed or overproduced by the RPE cells in DR[16] . It
could be used as a biomarker which is related to severity of
catalytic stress but as a response to it, not as a contributing
factor. In other words, an optimal concentration of Cys - C
may protect cells but if higher concentrations could be toxic is
unknown[43] . It is in contrast to previous proposals which
introduced the Cys - C as a contributing factor in DR
pathogenesis[15-16] . Obviously, findings of current study
should be confirmed by further larger studies. The main role
of Cys-C in pathogenesis of DR is not fully understood. To
elucidate the role of it in stressed cells, we suggested that
further studies to focus on association of Cys -C levels with
catalytic and oxidative products. In this scope, assessment of
correlation of Cys-C to levels of malondialdehyde (MDA),
advanced glycation end - products ( AGEs), their receptors
(RAGE), soluble RAGE ( sRAGE), and ferric reducing
ability of plasma (FRAP) is suggested[44] . If the Cys-C or
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other cysteine protease inhibitors could be used as therapeutic
agents in DM remains to be investigated.
Findings of this study were limited by small size of study, no
healthy control enrolment, single center design of study
(however the center is the only ophthalmic center of region),
blood pressure ( BP) levels of subjects also has not been
analyzed (there is a relation between BP, DR, and also Cys-
C in diabetics[45]), creatinine levels of subjects has not been
analyzed ( however none of subject had DN), body mass
index (BMI) of subjects has not been analyzed ( Cys -C is
moderately correlated with weight and weakly correlated with
height) and other inflammatory factors ( e. g. IL - 1beta,
IL-6, TNF-琢, VEGF, Von Willebrand factor, ADAMTS13,
and d - Dimer ) has not been investigated. Despite these
limitations, it is the first study that has investigated
association of Cys-C with ESR, hs-CRP, and DR in diabetic
patients who had not DN. Advances in understanding the role
of Cys - C in development of DR may improve screening,
diagnosis, prediction, follow up, and treatment of
retinopathy. Cys-C use in routine practice was limited by lack
of cut-off values, large number of clinical studies, guidelines
on indications of the test, and the cost-benefit balance of the
test[8] .
In summary, current study confirms findings of few available
studies that Cys-C levels were correlated with severity of DR.
The Cys-C was found to be risk factor of DR independently of
HbA1c, ESR, hs-CRP levels, and duration of disease. We
proposed that rise of Cys-C may be a protective response to
catalytic stress which diabetics are in. It is in contrast to
previous proposals that put forward a harming effect of
accumulated Cys - C on endothelial pump activity[16] .
Confirmation of these findings merits further larger studies. It
is also recommended that intravitreal level of Cys - C to be
measured in future, to elucidate if its level is corresponding to
systemic serum level or it is overproduced locally in eyes with
DR. Furthermore, we suggested that future studies to evaluate
association of Cys - C levels with MDA, AGEs, RAGE,
sRAGE, and FRAP[44] .
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